Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
FERA Pharmaceuticals, LLC v. Akorn, Inc. et al
Case Number:
1:12-cv-07694
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
January 30, 2018
Akorn, Fera, Perrigo Settle Trade Secrets, Antitrust Suit
Fera Pharmaceuticals LLC and Akorn Inc. have settled a $100 million trade secrets case tied to a supply agreement for eye infection treatments, along with antitrust counterclaims that brought Perrigo Co. PLC into the mix, ending the suit Monday, just weeks before a scheduled trial.
-
April 22, 2015
Perrigo Wants Akorn's Antitrust Counterclaims Tossed
Perrigo Company PLC urged a New York judge Wednesday to toss antitrust counterclaims brought by Akorn Inc. in a lawsuit that originally started when Fera Pharmaceuticals LLC lodged a $100 million trade secrets suit against Akorn, saying the allegations are deficient.
-
October 27, 2014
Fera's Injunction Claim Axed In $100M Trade Secret Suit
A New York federal judge on Friday trimmed a claim for injunctive relief from Fera Pharmaceuticals LLC's $100 million trade secrets and breach of contract suit against generic-drug maker Akorn Inc. after hearing counsel that morning.
-
July 30, 2013
Judge Won't Toss $100M Trade Secret Suit Against Akorn
A New York federal judge Monday denied generic-drug maker Akorn Inc.'s argument that a $100 million trade secrets and breach of contract suit filed by Fera Pharmaceuticals LLC was barred by the companies' supply agreement, ruling the agreement might have been induced by fraud, and therefore invalid.
-
January 28, 2013
Eye Med Distributor's $100M Suit Barred By Deal, Akorn Says
Generic-drug maker Akorn Inc. on Friday asked a New York federal court to dismiss most claims from Fera Pharmaceuticals LLC's $100 million suit accusing it of trade secrets theft, breach of a supply agreement and unfair competition, arguing the allegations were invalid or barred by the agreement.